Praecis Puts Brakes On Plenaxis, Explores Strategic Financing Options
Company will record $7.5 mil. in charges after announcing it will not enter a licensing or sale transaction for the prostate cancer therapy.
Company will record $7.5 mil. in charges after announcing it will not enter a licensing or sale transaction for the prostate cancer therapy.